Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.

Villa NY, Bais S, Chan WM, Meacham AM, Wise E, Rahman MM, Moreb JS, Rosenau EH, Wingard JR, McFadden G, Cogle CR.

Cytotherapy. 2016 Mar;18(3):465-80. doi: 10.1016/j.jcyt.2015.12.007.

PMID:
26857235
2.

Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells.

Kim S, Zingler M, Harrison JK, Scott EW, Cogle CR, Luo D, Raizada MK.

Hypertension. 2016 Mar;67(3):574-84. doi: 10.1161/HYPERTENSIONAHA.115.06474. Epub 2016 Jan 18.

PMID:
26781279
3.

Identification of Bone Marrow Cell Subpopulations Associated with Improved Functional Outcomes in Patients with Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.

Taylor DA, Perin EC, Willerson JT, Zierold C, Resende M, Carlson M, Nestor B, Wise E, Orozco A, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Traverse JH, Cooke JP, Schutt RC, Bhatnagar A, Grant MB, Lai D, Johnstone BH, Sayre SL, Moyé L, Ebert RF, Bolli R, Simari RD, Cogle CR.

Cell Transplant. 2015 Nov 19. [Epub ahead of print]

PMID:
26590374
4.

Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.

Cogle CR, Ortendahl JD, Bentley TG, Anene AM, Megaffin S, McKearn TJ, Petrone ME, Mukherjee S.

Expert Rev Pharmacoecon Outcomes Res. 2015 Nov 20:1-10. [Epub ahead of print]

PMID:
26589773
5.

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Cogle CR, Scott BL, Boyd T, Garcia-Manero G.

Oncologist. 2015 Dec;20(12):1404-12. doi: 10.1634/theoncologist.2015-0165. Epub 2015 Oct 13.

PMID:
26463870
6.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.

Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B.

Leukemia. 2015 Oct 7. doi: 10.1038/leu.2015.265. [Epub ahead of print]

PMID:
26442612
7.

Clinical significance of in vivo cytarabine-induced gene expression signature in AML.

Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE.

Leuk Lymphoma. 2015 Oct 16:1-12. [Epub ahead of print]

PMID:
26366682
8.

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

Laille E, Shi T, Garcia-Manero G, Cogle CR, Gore SD, Hetzer J, Kumar K, Skikne B, MacBeth KJ.

PLoS One. 2015 Aug 21;10(8):e0135520. doi: 10.1371/journal.pone.0135520. eCollection 2015.

9.

Bone marrow niche in the myelodysplastic syndromes.

Cogle CR, Saki N, Khodadi E, Li J, Shahjahani M, Azizidoost S.

Leuk Res. 2015 Oct;39(10):1020-7. doi: 10.1016/j.leukres.2015.06.017. Epub 2015 Jul 14. Review.

PMID:
26276090
10.

Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.

Drusbosky L, Gars E, Trujillo A, McGee C, Meacham A, Wise E, Scott EW, Cogle CR.

Leuk Res. 2015 Sep;39(9):984-9. doi: 10.1016/j.leukres.2015.05.015. Epub 2015 Jul 2.

11.

Incidence and Burden of the Myelodysplastic Syndromes.

Cogle CR.

Curr Hematol Malig Rep. 2015 Sep;10(3):272-81. doi: 10.1007/s11899-015-0269-y.

12.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators.

Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11.

13.

Acute myeloid leukemia in the vascular niche.

Cogle CR, Bosse RC, Brewer T, Migdady Y, Shirzad R, Kampen KR, Saki N.

Cancer Lett. 2015 May 8. pii: S0304-3835(15)00328-6. doi: 10.1016/j.canlet.2015.05.007. [Epub ahead of print]

PMID:
25963886
14.

Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.

Villa NY, Wasserfall CH, Meacham AM, Wise E, Chan W, Wingard JR, McFadden G, Cogle CR.

Blood. 2015 Jun 11;125(24):3778-88. doi: 10.1182/blood-2014-07-587329. Epub 2015 Apr 22.

15.

Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians.

Eldjerou LK, Cogle CR, Rosenau EH, Lu X, Bennett CA, Sugrue MW, Hoyne J, Lambert A, Ashley L, Sazama K, Fields G, Wingard JR, Zubair AC.

Transfusion. 2015 Jul;55(7):1766-71. doi: 10.1111/trf.13124. Epub 2015 Apr 22.

PMID:
25903156
16.

Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome.

Schmit JM, Turner DJ, Hromas RA, Wingard JR, Brown RA, Li Y, Li MM, Slayton WB, Cogle CR.

Leuk Res Rep. 2015 Apr 3;4(1):24-7. doi: 10.1016/j.lrr.2015.03.002. eCollection 2015.

17.

Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease.

Kim M, Rahman MM, Cogle CR, McFadden G.

Biochem Biophys Res Commun. 2015 Jul 10;462(4):283-7. doi: 10.1016/j.bbrc.2015.03.146. Epub 2015 Apr 2.

PMID:
25843801
18.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators.

Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23.

20.

Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.

Schutt RC, Trachtenberg BH, Cooke JP, Traverse JH, Henry TD, Pepine CJ, Willerson JT, Perin EC, Ellis SG, Zhao DX, Bhatnagar A, Johnstone BH, Lai D, Resende M, Ebert RF, Wu JC, Sayre SL, Orozco A, Zierold C, Simari RD, Moyé L, Cogle CR, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2015 Jan 2;116(1):99-107. doi: 10.1161/CIRCRESAHA.116.304710. Epub 2014 Nov 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk